Fresenius Kabi Revenue and Competitors

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies. \n\nWith its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. \nFresenius Kabi employs around 40,000 people worldwide. In 2019, the company reported sales of more than €6.9 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.\n\nFresenius Kabi is a global leader in our business segments. We offer employees of diverse cultures and backgrounds a wide range of fulfilling and challenging career and personal growth opportunities, both domestically and internationally. We work together in a spirit of partnership, personal commitment and integrity to create value. \n\nWe offer:\n• world-class, dedicated teams \n• an open-minded, creative, can-do culture \n• a variety of opportunities to grow with the business \n• the chance to make a difference in patients’ quality of life \n\nFresenius Kabi Community Guidelines and User Information:\nhttps://www.fresenius-kabi.com/documents/Community-Guidelines-and-User-Information-EN.pdf (English)\nhttps://www.fresenius-kabi.com/documents/Community-Guidelines-and-User-Information-DE.pdf (German)